Off Script: A Pharma Manufacturing Podcast

While the pharmaceutical industry has been slow to adopt continuous manufacturing, it appears to be gaining momentum.

Greg Slabodkin

Read by Brittany Duncan 

Enjoy the article Here: https://www.pharmamanufacturing.com/all-articles/article/55295669/flow-state-the-evolving-shape-of-continuous-manufacturing 

Hydrogenation can serve as a critical link in chemical synthesis, particularly between nitration and phosgenation. When integrated strategically, it helps enable safer, more efficient production processes.

To better understand this connection, we spoke with Dr. Luca Mantilli, R&D Chemist at Valsynthese, the fine chemicals division of Société Suisse des Explosifs Holding (SSE). Dr. Mantilli discussed how hydrogenation was implemented to bridge the gap between two of the company’s core hazardous chemistries: nitration and phosgenation.

Learn more about Valsynthese: https://www.valsynthese.ch/

The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.

The good — Thermo Fisher opens center to boost cell therapy development
The bad — FDA cites Aurobindo plant after Raleigh inspection
The ugly — Trump probes pharma imports as tariff threat looms

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week:

The good — Novartis to invest $23B in U.S. manufacturing and R&D, including seven new sites
The bad — U.S. urged to invest $15B to counter China’s biotech rise
The ugly — Trump signals ‘major’ tariffs on pharma, urging manufacturing shift back to U.S.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week:

The good — Cellares, Cabaletta validate automated CAR T production
The bad — FDA warns Aspen over sterility issues
The ugly — FDA rejects Hengrui, Elevar cancer combo again

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week:

The good — Axplora expands its antibody-drug conjugate (ADC) manufacturing capacity to support growing demand.

The bad — Merck KGaA’s CDMO business reports a decline

The ugly — The FDA issues a warning letter to Granules India over manufacturing violations

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week:

The good — Eli Lilly expands manufacturing to boost supply

The bad — FDA blocks imports from two Indian API makers over manufacturing violations

The ugly — ICU Medical recalls potassium chloride injection bags over labeling error

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  

The good — Novartis boosts Slovenia investment to $3.6B

The bad — Trump tariffs unsettle biopharma FDI

The ugly — FDA warns Global Calcium, blocks US imports

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  

The good — FDA approves Opdivo subcutaneous version

The bad — Marinus Pharmaceuticals sells operations

The ugly — Novo Nordisk pushes back against compounding pharmacies